Biotech Co.* |
Pharma Co. (Country) |
Type/Product Area |
Terms/Details (Date) |
| |||
Abgenix Inc. (ABGX) |
AstraZeneca plc (UK) |
Broad collaboration on development of fully human antibodies for up to 36 cancer targets |
AstraZeneca, which gets worldwide commercialization rights, agreed to purchase $100M in Abgenix stock at $30 per share and up to another $60M in stock upon achievement of milestones; Abgenix also could get milestones of $50M for each product; there also is a co-promotion component (10/16) |
|
|||
Avera Pharmaceuticals Inc.* |
Novartis AG (Switzerland) |
License agreement under which Areva gained rights to a Phase II compound for anxiety and depression |
Novartis received an undisclosed up-front payment and equity stake in Areva and could get milestone and royalty payments (10/28) |
|
|||
Biogen Inc. (BGEN) |
Fumapharm AG (Switzerland) |
License to oral therapy for second-generation fumarate derivative entering Phase III trial in Europe |
Biogen gains worldwide rights except for Germany, where a first-generation product already is approved as Fumaderm (10/1) |
|
|||
Biota Holdings Ltd. (Australia; ASX:BTA) |
Sankyo Co. Ltd. (Japan) |
Collaboration pooling the flu drugs FluNet from Biota and R118958 from Sankyo |
Companies will pool their long-acting influenza drugs into single pipeline, which will be available for partnerships; any revenues would be shared equally (10/3) |
|
|||
BioVision AG* (Germany) |
AstraZeneca plc (UK) |
Collaboration to discover biomarkers for inflammatory disease |
BioVision will apply its phenotyping approach in the deal, terms of which were not disclosed (10/8) |
|
|||
BTG International Inc. (LSE:BGC) |
Sankyo Co. Ltd. (Japan) |
BTG acquired rights to preclinical compounds representing three approaches to treating Alzheimer's disease |
Terms of the deal were not disclosed; BTG intends to continue preclinical develoment and to look for a development partner (11/6) |
|
|||
Cardiome Pharma Corp. (Canada; TSE:COM) |
Fujisawa Healthcare Inc. |
Partnership covering Cardiome's RSD1235, a Phase III drug for atrial fibrillation and flutter |
Fujisawa gained rights in North America in exchange for paying $10M up front, $4M in an equity purchase, and up to $54M in development and commercial milestones; Cardiome also would get royalties (10/16) |
|
|||
Celera Diagnostics (joint venture of Celera Genomics Inc.; NYSE:CRA and Applied Biosystems Group; NYSE:ABI) |
Merck & Co.Inc. |
To identify and validate genetic markers useful in prognostic tests for certain cancers |
Celera gets access to gene expression data from Merck subsidiary Rosetta Inpharmatics LLC, while Merck gets access to Celera research data useful in developing cancer drugs; terms were not disclosed (10/20) |
|
|||
ChemBridge Research Laboratories LLC* |
GlaxoSmithKline plc (UK) |
Purchase agreement under which GSK gains access to CRL's GPCR Targeted Library |
Terms were not disclosed (11/18) |
|
|||
Chiron Corp. (CHIR) |
Pfizer Inc. |
Pfizer got a nonexclusive license to develop drugs against certain hepatitis C virus targets |
As part of the deal, Chiron and Pfizer unit Agouron Pharmaceuticals Inc. settled patent litigation; terms were not disclosed (10/28) |
|
|||
CIMA Labs Inc. (CIMA) |
Taiho Pharmaceutical Co. (Japan) |
License to Japanese rights to CIMA's OraVescent Fentanyl for breakthrough cancer pain |
Taiho licensed rights in Japan; CIMA could earn development and milestone payments, as well as revenue on sales to Taiho and royalties on sales; specific terms were not disclosed (11/12) |
|
|||
Corgentech Inc.* |
Bristol-Myers Squibb Co. |
Agreement to jointly develop and commercialize Corgentech's E2F Decoy, which is in Phase III for vein graft failure |
BMS is paying $45M up front in cash and equity, and up to $205M in clinical and regulatory milestones; the companies would share rights in the U.S., and BMS would pay royalties on sales elsewhere (10/13) |
|
|||
CoTherix Inc.* (formerly Exhale Therapeutics Inc.) |
Schering AG (Germany) |
CoTherix acquired exclusive U.S. rights to Ventavis (iloprost), a synthetic prostacyclin analogue |
CoTherix would pay royalties on U.S. sales; further terms were not disclosed on the product for primary pulmonary hypertension that is approved in Europe (10/14) |
|
|||
C Sixty Inc.* |
Merck & Co. Inc. |
Exclusive research license, supply agreement and commercial license option to develop drugs based on C Sixty's fullerene antioxidants |
Neither terms nor the two therapeutic areas involved was disclosed (10/16) |
|
|||
Cyntellect Inc.* |
Eli Lilly and Co. |
Agreement under which Lilly will use Cyntellect technology to implement high-throughput RNAi studies to evaluate gene target function |
Lilly will use the Laser Enabled Analysis and Processing technology; terms were not disclosed (10/4) |
|
|||
DeCode Genetics Inc. (Iceland; DCGN) |
Bayer AG (Germany) |
DeCode acquired an exclusive license to develop a small-molecule drug, DG031, against a target implicated in myocardial infarction |
DeCode plans to initiate a Phase II trial in 2004; Bayer is eligible to receive milestone and royalty payments; the target is made by a gene isolated by DeCode (11/16) |
|
|||
Dharmacon Inc.* |
Bayer Pharmaceuticals Corp. |
Agreement under which Dharmacon will supply custom siRNA reagents to Bayer |
Bayer will use the technology in target validation research; terms were not disclosed (11/11) |
|
|||
Dharmacon Inc.* |
Rosetta Inpharmatics LLC (unit of Merck & Co. Inc.) |
Collaboration to study factors affecting utility of short interfering RNA reagents for gene silencing |
Dharmacon retains rights to commercialize certain discoveries from the collaboration; further terms were not disclosed (10/8) |
|
|||
Discovery Partners International Inc. (DPII) |
AstraZeneca plc (UK) |
License agreement for DPI's patents covering in vitro gene expression profiling for indicating toxicity |
AstraZeneca gained nonexclusive worldwide rights; terms were not disclosed (9/25) |
|
|||
IBC Pharmaceuticals Inc. (subsidiary of Immunomedics Inc.; IMMU) |
Schering AG (Germany) |
Research collaboration to study bispecific antibodies for targeted cancer therapy |
Joint research studying a Schering antibody with IBC bispecific technology; companies will share resulting technology; terms were not disclosed (10/23) |
|
|||
Galapagos Genomics NV* (Belgium) |
Wyeth |
Collaboration under which Galapagos will discover and validate drug targets that drive bone formation |
Galapagos will use its osteoporosis know-how and SilenceSelect gene knock-down platform in the effort; Wyeth got exclusive rights to license the discoveries for osteoarthritis drug development in return for up-front, research and potential milestone payments totaling $40M (11/13) |
|
|||
Galapagos Genomics NV* (Belgium) |
Boehringer Ingelheim GmbH (Germany) |
Collaboration under which BI will use Galapagos technology to screen genes that influence viral replication |
Galapagos is supplying its SilenceSelect gene knockdown platform that targets more than 4,000 druggable genes; Galapagos gets up-front access fees and could earn further option andlicense fees (11/11) |
|
|||
GenPath Pharmaceuticals Inc.* |
Merck & Co. Inc. |
Collaboration under which GenPath will use its cancer models to identify tumor- maintenance genes suitable for small-molecule development |
GenPath will receive up-front and research payments, as well as potential milestones, that could total $100M; Merck gets an exclusive option to worldwide license rights, and would pay royalties on sales (11/17) |
|
|||
Guilford Pharmaceuticals Inc. (GLFD) |
Merck & Co. Inc. |
Agreement giving Guilford U.S. rights to Aggrastat (tirofiban hydrochloride) injection for platelet-mediated cardiovascular disease |
Guilford is paying $84M up front as well as sales royalties until 2012; Merck will manufacture product for Guilford (10/29) |
|
|||
Large Scale Biology Corp. (LSBC) |
Schering-Plough Animal Health Corp. |
Exclusive collaboration to evaluate vaccines for the control of viral infections in animals |
Large Scale will provide vaccine antigens that Schering-Plough will evaluate; the deal includes an option under which Large Scale would manufacture and supply vaccine for trials and commercialization (10/28) |
|
|||
MacroChem Corp. (MCHM) |
Novartis AG (Switzerland) |
Evaluation of product candidate combining MacroChem's SEPA technology with an undisclosed Novartis compound |
Additional testing is beginning following successful completion of the first phase (10/8) |
|
|||
Mannkind Corp.* |
Novo Nordisk A/S (Denmark) |
Agreement on a feasibility study of a pulmonary formulation of a therapeutic protein using Mannkind's Technosphere delivery technology |
The agreement focuses on development of an inhalable formulation of a Novo drug; terms were not disclosed (11/14) |
|
|||
Medarex Inc. (MEDX) |
BioWa Inc. (subsidiary of Kyowa Hakko Kogyo Co. Ltd.; Japan) |
Medarex licensed use of BioWa's antibody-dependent cellular cytotoxicity technology, Potelligent |
Medarex has options for exclusive licenses; it will apply the technology to certain antibodies; terms were not disclosed (10/16) |
|
|||
Medivir AB* (Sweden; SSE:MVIR) |
Jiangsu Hengrui Medicine Co. (China) |
Discovery collaboration to jointly develop products for chronic obstructive pulmonary disease |
The deal combined Medivir's program in protease inhibition and other technologies with Jiangsu's medicinal chemistry expertise; Jiangsu has rights to resulting products in China and Medivir in the rest of the world (11/19) |
|
|||
Medivir AB* (Sweden; SSE:MVIR) |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Collaboration on a research program in the area of hepatitis C virus |
Roche will provide financial support for the program and pay potential milestone and royalty payments to Medivir; Medivir retains marketing rights in the Nordic countries (11/19) |
|
|||
Meridica Ltd.* (UK) |
Pfizer Inc. |
Pfizer licensed Meridica's dry-powder inhaler, Xcelovair, for use in products for respiratory diseases |
Pfizer is making an undisclosed up-front payment and could pay milestones and royalties; it also is taking an equity stake in Meridica (10/20) |
|
|||
MethylGene Inc.* (Canada) |
Taiho Pharmaceutical Co. Ltd. (Japan) |
Collaboration and license agreement for development of a small-molecule inhibitor program against histone deacetylases for cancer |
MethylGene receives an up-front license fee and equity investment of $3.75M, and Taiho will fund research for at least two years and pay milestones up to $16.25M in exchange for rights in much of Asia; MethylGene retains rights elsewhere (10/20) |
|
|||
Momenta Pharmaceuticals Inc.* |
Sandoz Inc. (unit of Novartis AG; Switzerland) |
Alliance covering joint product development arising from Momenta's expertise in complex sugars and Sandoz's position in generics |
Momenta would receive a share of any sales resulting from the effort; Sandoz will pay development costs and make certain other payments to Momenta (11/18) |
|
|||
MorphoSys AG (Germany; FSE:MOR) |
Boehringer Ingelheim GmbH (Germany) |
BI exercised its option to license to a therapeutic antibody in the area of inflammatory disease |
The deal follows work started in February; BI will take over development of the antibody and would pay undisclosed milestone and royalty payments to MorphoSys (11/18) |
|
|||
Myogen Inc.* |
Novartis AG (Switzerland) |
Research collaboration to discover and develop drugs for cardiovascular disease |
Novartis is paying undisclosed up-front fees and funding research for at least three years in exchange for the exclusive right to license targets and compounds; Myogen could get additional license fees, milestone payments and sales royalties, and has an option on certain co-promotion rights (10/13) |
|
|||
Neose Technologies Inc. (NTEC) |
Novo Nordisk A/S (Denmark) |
Two agreements to use Neose's GlycoPEGylation technology to develop three next-generation proteins |
License agreements follow work begun in 2002; Neose is getting $4.3M up front and up to $51.3M in milestone payments; Novo is covering the cost of the work and would pay royalties on sales (11/17) |
|
|||
Neurome Inc.* |
Wyeth |
Research agreement under which Neurome will use its quantitative neuropathology know-how to help Wyeth in its CNS discovery programs |
Neurome will receive research funding under the terms of the multiyear agreement (10/29) |
|
|||
Norwood Abbey Ltd. (Australia; ASX:NAL) |
TAP Pharmaceutical Products Inc. |
Exclusive license agreement giving TAP rights to Norwood's immunology technology for enhancement of an existing class of sex steroid drugs called GnRH analogues |
Norwood received a $2M equity investment and could get milestone and royalty payments; the companies will explore new indications for TAP's Lupron Depot using the Norwood technology (11/11) |
|
|||
Peninsula Pharmaceuticals Inc. * |
Takeda Chemical Industries Ltd. (Japan) |
Licensing agreement on TAK-599, a preclinical broad- spectrum antibiotic from the cephalosporin class |
Takeda gained a worldwide exclusive license outside Japan, and will manufacture product; terms were not disclosed (9/30) |
|
|||
Serenex Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Research agreement under which Serenex will screen Roche compounds against protein targets |
Roche gets access to Serenex's Proteome Mining and Functional Proteome Fractionation technologies; terms were not disclosed (11/10) |
|
|||
Sunesis Pharmaceuticals Inc.* |
Dainippon Pharmaceutical Co. Ltd. (Japan) |
Exclusive worldwide license agreement for cancer drug SPC-595, from the naphthyridines class |
Sunesis is making an undisclosed up-front payment and would pay milestones and royalties; specific terms were not disclosed (10/15) |
|
|||
Syrrx Inc.* |
PPD Inc. |
Agreement to jointly develop Syrrx-designed human dipeptidyl-IV inhibitors for Type II diabetes and other diseases |
PPD invested $25M in Syrrx convertible preferred stock and will fund most of the work through Phase II; the companies would share costs of Phase III work, as well as any resulting profits; Syrrx also can earn milestone payments (11/19) |
|
|||
TaiGen Biotechnology Co. Ltd.* (Taiwan) Tanox Inc. (TNOX) |
TTY Biopharm Co. Ltd. (Taiwan) Wyeth |
Agreement to jointly develop and market a topoisomerase-I inhibitor, DB67 Agreement to develop drugs for osteoporosis based on a Tanox target gene |
TaiGen will handle most of the preclinical work and TTY the later-stage work; they plan to jointly market in Asia (10/20) Wyeth will develop a small molecule against the target and Tanox will develop an antibody-based drug in parallel; Tanox will get a $1M up-front payment; other terms were not disclosed (11/13) |
|
|||
Transition Therapeutics Inc. (Canada; TSE:TTH) |
Novo Nordisk A/S (Denmark) |
Option agreement for exclusive license to TTI's Islet Neogenesis Therapy |
Decision on option is expected in 3Q:04; Novo paid $500,000 and would pay $5 million up front in license and equity fees and up to $51.5M more in milestone payments if it exercises option, along with commercial milestones and royalties (11/7) |
|
|||
Vion Pharmaceuticals Inc. (VION) |
Beijing Pason Pharmaceuticals Inc. (China) |
Exclusive license to Triapane for anticancer and antiviral uses in China |
Vion will get $500,00 up front and milestone payments up to $4.75M, as well as royalties of 11% on sales in China (10/21) |
|
|||
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; FSE: Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE: Toronto Stock Exchange. |